Research programme: hydroxyl dendrimer therapeutics - Ashvattha therapeutics
Alternative Names: HDTs - Ashvattha Therapeutics; Hydroxyl dendrimers - Ashvattha TherapeuticsLatest Information Update: 23 Jun 2022
At a glance
- Originator Ashvattha Therapeutics
- Class Anti-inflammatories; Antineoplastics; Dendrimers
- Mechanism of Action Macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain cancer; Inflammation; Plexiform neurofibroma